Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT vs MMAE-based ADCs in Advanced Urothelial Carcinoma (SPARE-UC-01)
NCT07662863Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in urothelial carcinoma (UC), sponsored by Fudan University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07662863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662863.